Norwegian National Headache Centre, Trondheim University Hospital, 7006 Trondheim, Norway.
J Headache Pain. 2009 Dec;10(6):395-406. doi: 10.1007/s10194-009-0156-9. Epub 2009 Oct 1.
After the triptans, a calcitonin gene-related peptide blocker (telcagepant) is the first acute medicine that has been developed primarily for treatment of acute migraine. Otherwise, the new drugs have been developed first for other purposes, like anticonvulsants, antihypertensives and antidepressants used for migraine prophylaxis. For acute attacks, a new way to administer a traditional drug like dihydroergotamine is under way, and documentation of efficacy in migraine has been gained for some commonly used painkillers and anti-inflammatory drugs, and for some herbal extracts. Based on insights into the basic pathophysiological mechanisms of the disorder, some drugs have been developed which seem promising in early phase II studies (NOS inhibitors and 5HT1F-receptor agonists). In the future, development and enhancements of existing medicines must be accompanied by increased efforts to develop truly new migraine drugs based on knowledge of the pathophysiology if one wishes to reduce substantially the great burden migraine poses on patients and society.
在曲坦类药物之后，降钙素基因相关肽阻滞剂（telcagepant）是第一种主要用于治疗急性偏头痛的急性药物。此外，新药最初是为其他用途开发的，例如抗惊厥药、抗高血压药和用于偏头痛预防的抗抑郁药。对于急性发作，正在尝试一种新的方法来管理传统药物二氢麦角胺，并且一些常用的止痛药和消炎药以及一些草药提取物在偏头痛方面的疗效也得到了证实。基于对该疾病基本病理生理机制的深入了解，一些药物在早期 II 期研究中似乎很有前途（NOS 抑制剂和 5HT1F-受体激动剂）。未来，如果要大大减轻偏头痛给患者和社会带来的巨大负担，除了开发和改进现有药物之外，还必须加大力度基于病理生理学知识来开发真正的新型偏头痛药物。
